A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation. [PDF]
Liu Q +7 more
europepmc +1 more source
Clinical Impact of Febuxostat in HFpEF Versus HFrEF: Insights from a Prospective Cohort. [PDF]
Ahsaan F, Latif B, Rehman Z.
europepmc +1 more source
Soluble uric acid suppresses neutrophil-mediated host defense in sepsis. [PDF]
Li Q +11 more
europepmc +1 more source
Response to Febuxostat in Elderly Gout Patients with Clinical Subtypes of Hyperuricemia: A Prospective Cohort Study. [PDF]
Li J +10 more
europepmc +1 more source
Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes. [PDF]
Pu Z +7 more
europepmc +1 more source
Formulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells). [PDF]
Sakran W +2 more
europepmc +1 more source
Hepatic Safety of Febuxostat and Allopurinol in Gout Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]
Dewi C +5 more
europepmc +1 more source
Effects of adding urinary alkalizer citrate mixture to febuxostat in gout patients with combined-type hyperuricemia and low urine pH: a prospective cohort study. [PDF]
Guo K +17 more
europepmc +1 more source
Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes. [PDF]
Yi Y, Yang J, Chen Y, Liu H, Deng Y.
europepmc +1 more source
Transcatheter arterial microembolization for refractory chronic pain associated with familial gouty tophi: a case report with 2-year follow-up. [PDF]
Sugihara E +6 more
europepmc +1 more source

